BioClinica acquires MediciGroup
BioClinica, a specialty clinical trials services and technology provider, has acquired a global patient recruitment and retention firm, MediciGroup (Medici). The acquisition includes affiliates MediciGlobal and Access to Patients. Medici also provides a lost-to-follow-up patient locate service (L2FU) that finds missing patients globally. Together with Medici, BioClinica will offer pharmaceutical companies comprehensive patient recruitment and retention services that improve the speed and efficiency of global clinical trials.
John Hubbard, Ph.D., BioClinica CEO, said, "Medici's proprietary technologies and processes ensure eligible patients are enrolled and retained in clinical trials, further accelerating clinical development timelines. As one company, we will bring to our customers a new clinical services model that is thoughtfully designed to achieve high-performance efficiencies in global trials."
Medici manages over 30 global patient communities online which, along with their patented tools and cutting-edge digital methodologies, help clients meet or exceed their recruitment goals. The company has implemented more than 200 programs for some of the world's largest pharmaceutical companies since its founding in 1992. Medici is distinguished by the quality of patients sent to sites based on a multi-step screening process using patented tools and digital methods. Its proprietary L2FU technology maintains clinical trial integrity and minimizes missing patient data by significantly reducing the number of patients lost to follow-up.
"We not only find your patients we help keep them," said Liz Moench, founder and CEO, Medici. "Together with BioClinica, our services will deliver an important model focused on speed, quality and cost efficiency for clinical trials implementation."
BioClinica and Medici already have worked together on studies where the Medici Global team has leveraged data from BioClinica's technology. The two companies recently collaborated to complete enrollment for a global study ahead of schedule.
"When we integrate our recruitment metrics with BioClinica's system, we can manage clinical trials in real time. This enables us to monitor enrollment rates by sites and drive performance at all levels recruitment marketing and site performance from start to end," said Moench.
Moench will lead the company's global patient recruitment and retention services, headquartered at BioClinica's Philadelphia-area office.